NCT02469701

Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease

Nivolumab and Ablation For Patients With Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease: A Brown University Oncology Research Group Phase II Study

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: howard safran · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Nivolumab releases the inhibition of the immune system against human cancers. Dramatic and sustained activity has been observed in advanced lung cancer. Ablation may stimulate the immune system by exposing new tumor antigens. Since tumors that express PD-L1 may be more likely to respond to nivolumab, if ablation increases PD-L1 expression (which has not been studied) this treatment may enhance the activity of nivolumab at both the treated site and in other, non-treated, tumors. Ablation is already an FDA approved treatment for cancer. Nivolumab was recently FDA approved for second line treatment of advanced squamous cell NSCLC. The goal of the study will be to determine if the combination of nivolumab and ablation has higher systemic activity than previously reported with nivolumab alone.

Detailed description

See summary above

Conditions

• Non-small Cell Lung Cancer
• Lung Cancer
• Metastatic Lung Cancer
• NSCLC

Interventions

Type	Name	Description
DRUG	nivolumab and ablation

Timeline

• Start date: 2016-02-01
• Primary completion: 2017-07-01
• Completion: 2018-03-01
• First posted: 2015-06-11
• Last updated: 2020-02-17
• Results posted: 2018-05-07

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study